Compare Davita Inc (DVA) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs KKR & Co Inc — how do they compare? Davita Inc trades at $179.32 (market cap $11.29B), while KKR & Co Inc trades at $91.49 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 7.1× Davita Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and KKR & Co Inc for 67 Days on average.
| DVA | KKR | |
|---|---|---|
Market Cap | $11.29B | $80.39B |
Volume | 582,204 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $240.96 | $142.75 |
52-Week Low | $103.87 | $83.88 |
Typical Hold Time | 113 Days | 67 Days |
Enterprise Value | $24.01B | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
KKR trades at $89.67, down 1.1% on the day, with strong analyst support (89% buy ratings) and a $123.30 consensus price target suggesting 38% upside. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. The company maintains solid profitability with 14.97% net income margin and 10.99% ROE, while recent business developments include strategic joint ventures and asset sales across global markets.
KKR presents a compelling investment case with strong institutional backing and consistent earnings growth, though technical indicators show bearish momentum. Key risks include market volatility and execution challenges in global investments. The significant discount to analyst targets and recent strategic moves position the stock for potential recovery despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
